IP Verse

Takeda Pharmaceutical Company Limited opposition analysis

COMPANY ANALYSIS

Latest oppositions filed by Takeda Pharmaceutical Company Limited

Patent Number:
EP3377103
Title:
Functional Antibody Fragment Complementation For A Two-Components System For Redirected Killing Of Unwanted Cells
Applicant:
REVITOPE LIMITED
Opposition Date:
Dec 17, 2021

Latest patents of Takeda Pharmaceutical Company Limited opposed by its competitors

Patent:
EP3370729
Grant Date:
Sep 27, 2023
Title:
Methods For The Identification, Evaluation And Treatment Of Patients Having Multiple Myeloma
Oppositions:
1
Patent:
EP3263110
Grant Date:
May 10, 2023
Title:
Solid Preparation
Oppositions:
1
Patent:
EP3518933
Grant Date:
Mar 16, 2022
Title:
Methods Of Treating Uterine Fibroids And Endometriosis
Oppositions:
1
Patent:
EP3521422
Grant Date:
Oct 6, 2021
Title:
Substantially Animal Protein-Free Recombinat Furin And Methods For Producing Same
Oppositions:
1
Patent:
EP3626258
Grant Date:
Aug 4, 2021
Title:
Methods And Compositions For Cns Delivery Of Iduronate-2-Sulfatase
Oppositions:
1
Patent:
EP3103469
Grant Date:
Dec 9, 2020
Title:
Cns Delivery Of Therapeutic Agents
Oppositions:
1
Patent:
EP3060582
Grant Date:
Sep 23, 2020
Title:
Assays For Determining Plasma Kallikrein System Biomarkers
Oppositions:
1
Patent:
EP3121266
Grant Date:
Apr 22, 2020
Title:
Oligopeptide-Free Cell Culture Media
Oppositions:
6
Patent:
EP2094246
Grant Date:
Apr 1, 2020
Title:
Sustained-Release Composition And Method For Producing The Same
Oppositions:
1
Patent:
EP3071219
Grant Date:
Nov 14, 2018
Title:
Methods Of Treating Antibody-Mediated Rejection In Organ Transplant Patients With C1-Esterase Inhibitor
Oppositions:
1

Competitors of Takeda Pharmaceutical Company Limited

GREEN CROSS CORPORATION

SANDOZ AG

BREUER, MARKUS

Want to track Takeda Pharmaceutical Company Limited?

Feel free to send us a message here and we will get back to you